Drug Topics survey finds R.Ph.s approve of BTC class of drugs

December 12, 2007

Drug Topics poll: R.Ph.s favor BTC class of drugs

Pharmacists appear in favor of a behind-the-counter (BTC) class of drugs, according to an exclusive Drug Topics' online poll conducted in November. Drug Topics' received 659 responses to the question, Should FDA approve a behind-the-counter (BTC) class of drugs? Thirty percent of pharmacists said, Yes, since it will reduce healthcare costs by eliminating the need for a doctor's visit. Fifteen percent said, Yes, it will increase pharmacies' foot traffic and enhance pharmacists' authority; and 19% said Yes, many other countries have successfully established such a class of drugs. On the other hand, 6% opposed a BTC class because pharmacists don't have the time to counsel patients on these drugs; 22% said, until there is reimbursement, it's unrealistic to expect pharmacists to counsel patients on these drugs; and 6% said we don't have enough evidence of the safety and efficacy of a BTC class of drugs. Finally 2% said they "don't know" whether a BTC class is a good idea or not.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.